Today’s Stock Alert: Epizyme Inc Can’t Be More Risky. Trades Sigfnicicantly Lower

Today's Stock Alert: Epizyme Inc Can't Be More Risky. Trades Sigfnicicantly Lower

The stock of Epizyme Inc (NASDAQ:EPZM) is a huge mover today! About 205,588 shares traded hands. Epizyme Inc (NASDAQ:EPZM) has risen 3.05% since April 27, 2016 and is uptrending. It has underperformed by 2.18% the S&P500.
The move comes after 6 months negative chart setup for the $649.42M company. It was reported on Nov, 30 by We have $10.01 PT which if reached, will make NASDAQ:EPZM worth $58.45M less.

Analysts await Epizyme Inc (NASDAQ:EPZM) to report earnings on March, 8. They expect $-0.62 earnings per share, down 16.98% or $0.09 from last year’s $-0.53 per share. After $-0.42 actual earnings per share reported by Epizyme Inc for the previous quarter, Wall Street now forecasts 47.62% negative EPS growth.

Epizyme Inc (NASDAQ:EPZM) Ratings Coverage

Out of 7 analysts covering Epizyme (NASDAQ:EPZM), 7 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Epizyme has been the topic of 9 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The rating was maintained by RBC Capital Markets with “Outperform” on Monday, September 28. The firm earned “Market Outperform” rating on Wednesday, March 9 by JMP Securities. The firm has “Buy” rating given on Tuesday, August 25 by Zacks. The firm has “Buy” rating given on Tuesday, May 10 by Mizuho. The stock of Epizyme Inc (NASDAQ:EPZM) has “Buy” rating given on Thursday, August 6 by Mizuho. H.C. Wainwright upgraded the stock to “Buy” rating in Monday, March 14 report. Citigroup initiated the shares of EPZM in a report on Tuesday, April 5 with “Buy” rating.

According to Zacks Investment Research, “Epizyme, Inc. is a biopharmaceutical company. It engages in the discovery, development, planning, and commercialization of therapeutics for cancers. Epizyme, Inc. is headquartered in Cambridge, Massachusetts.”

Insitutional Activity: The institutional sentiment decreased to 1.09 in 2016 Q2. Its down 0.55, from 1.64 in 2016Q1. The ratio dived, as 8 funds sold all Epizyme Inc shares owned while 20 reduced positions. 14 funds bought stakes while 32 increased positions. They now own 45.74 million shares or 3.00% more from 44.40 million shares in 2016Q1.
Moreover, Zacks Investment Mgmt has 0.01% invested in Epizyme Inc (NASDAQ:EPZM) for 17,003 shares. Nea Co Llc accumulated 6.26 million shares or 3.33% of the stock. Macquarie Grp Limited last reported 20,000 shares in the company. Swiss Savings Bank holds 0% or 56,500 shares in its portfolio. Blackrock Institutional Tru Na accumulated 0% or 828,299 shares. Moreover, Dekabank Deutsche Girozentrale has 0% invested in Epizyme Inc (NASDAQ:EPZM) for 33,100 shares. Ecor1 Capital Limited Company has 3.05% invested in the company for 755,046 shares. Franklin Resources holds 0.01% or 1.20M shares in its portfolio. The United Kingdom-based Oxford Asset Mngmt has invested 0.06% in Epizyme Inc (NASDAQ:EPZM). Alps Inc holds 0.01% or 80,387 shares in its portfolio. Legal And General Grp Plc owns 7,475 shares or 0% of their US portfolio. The New York-based Ny State Common Retirement Fund has invested 0% in Epizyme Inc (NASDAQ:EPZM). Northern Tru Corporation has invested 0% of its portfolio in Epizyme Inc (NASDAQ:EPZM). Deutsche Bankshares Ag has 0% invested in the company for 93,576 shares. Nationwide Fund Advisors last reported 0% of its portfolio in the stock.

Insider Transactions: Since June 9, 2016, the stock had 0 insider buys, and 8 insider sales for $141,970 net activity. Singer Andrew E. also sold $12,656 worth of Epizyme Inc (NASDAQ:EPZM) on Thursday, June 9. On Tuesday, July 5 the insider Copeland Robert A sold $40,128.

Another recent and important Epizyme Inc (NASDAQ:EPZM) news was published by which published an article titled: “Why Epizyme Inc, Akebia Therapeutics Inc, and Cempra Inc Got Wacked Today” on January 07, 2016.

EPZM Company Profile

Epizyme, Inc., incorporated on November 1, 2007, is a clinical-stage biopharmaceutical company. The Firm discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. The Firm develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs. The Firm develops small molecule inhibitors of other chromatin modifying proteins, or CMPs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment